Norak Biosciences Purchases Second IN Cell Analyzer 3000 from Amersham Biosciences.Business Editors/High-Tech Writers PISCATAWAY, NJ--(BUSINESS WIRE)--May 7, 2003 Norak Chooses Additional IN Cell Analyzer 3000 to Support New Screening Collaboration Business Norak Biosciences, Inc. (Norak) of Research Triangle Park Research Triangle Park, research, business, medical, and educational complex situated in central North Carolina. It has an area of 6,900 acres (2,795 hectares) and is 8 × 2 mi (13 × 3 km) in size. Named for the triangle formed by Duke Univ. , NC, has purchased a second IN Cell Analyzer 3000 system from Amersham Biosciences, the life sciences business of Amersham (LSE LSE - Language Sensitive Editor :, NYSE NYSE See: New York Stock Exchange :, OSE OSE - Open Systems Environment : AHM AHM Automated Hacking Machines AHM All Hands Meeting AHM Academy for Healthcare Management AHM Atom Heart Mother (Pink Floyd album) AHM Airport Handling Manual AHM Acutely Hazardous Material AHM Anti-Helicopter Mine ), to further support its internal drug discovery program and new screening collaboration business Norak's purchase of an additional IN Cell Analyzer 3000 imaging system will enable the company to expand its capacity for performing high throughput, high content subcellular sub·cel·lu·lar adj. 1. Situated or occurring within a cell: subcellular organelles. 2. Smaller in size than ordinary cells: subcellular organisms. 3. screening for its internal drug discovery program. The second cellular imaging system will also support its new screening collaboration business, which will provide the pharmaceutical and biotechnology industries with access to Norak's Transfluor (R) technology and its large, diverse compound library. "We have a great deal of experience already with the IN Cell Analyzer 3000 and have been very impressed by its high throughput and sensitivity ideally matched with the benefits of our Transfluor(R) technology," says Terry E. Willard, Executive Vice President at Norak Biosciences. "We have already optimized many applications of Transfluor(R) for maximal performance on the IN Cell Analyzer 3000. The additional capacity of a second system will support our new screening collaboration business with its rapid imaging capabilities." "Norak's choice of the IN Cell Analyzer 3000 to drive its new drug screening service demonstrates the value and leadership of our advanced imaging system in the drug discovery marketplace," says Cathy Howat, Vice President Marketing Cell Analysis and Screening at Amersham Biosciences. "The combination of IN Cell Analyzer 3000's high throughput and exquisite sensitivity has allowed Norak to optimize the performance of its Transfluor technology and to expand into contract screening." Norak's Transfluor(R) technology is a patented, universal GPCR GPCR Guanine Nucleotide-Binding Protein-Coupled Receptor GPCR GTP-binding Protein-Coupled Receptor drug discovery technology designed to be the most direct and accurate method for screening potential drug candidates against GPCR targets, whether known or orphan. Amersham Biosciences' IN Cell Analyzer 3000 is a highly advanced imaging tool that uses a laser-based confocal confocal see confocal microscopy. imaging system to enable high throughout, high content testing of drug compounds on live or fixed cells. The combination of rapid imaging and sophisticated computer algorithms capable of real-time image analysis enables the IN Cell Analyzer 3000 to generate and interpret more than 35,000 three-color cellular images in less than 24 hours. Norak Biosciences, Inc., headquartered in Research Triangle Park, NC, is a private biotechnology company. Norak is utilizing its proprietary Transfluor(R) technology to become a world leader in the discovery and development of drugs that regulate G protein-coupled receptors. For more information about Norak Biosciences, Inc., please visit the Company's website at www.norakbio.com Amersham Biosciences, the life sciences business of Amersham plc Amersham plc was a UK pharmaceutical company, specializing in medical diagnostics and life science products. The company was formed in 1997 by merging Amersham International (U.K.), Pharmacia Biotech (Sweden) and Nycomed (Norway). (LSE: NYSE: OSE: AHM), is a world leader in developing and providing integrated systems and solutions for disease research, drug development and manufacture. Our systems are used to uncover the function of genes and proteins, for the discovery and development of drugs and for the manufacture of biopharmaceuticals. The customers for Amersham Biosciences' products and technology are pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. and research and academic institutions, principally in North America, Europe, Latin America and Asia. More information about Amersham Biosciences is available at www.amershambiosciences.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion